Inhaled Sevoflurane for ARDS Prevention

Exclusion Criteria

• •Patient under judicial protection, guardianship or supervision, as defined by art L1121-8 of the Public Health Code
• •Patient under psychiatric care as defined by art. L1121-6 of the Public Health Code
• •Patient deprived of their freedom by judiciary or administrative order
• •Known pregnancy
• •Presence of ARDS prior to randomization
• •Endotracheal ventilation for greater than 24 hours prior to randomization
• •Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep-disordered breathing
• •Tidal volume of 6 mL/kg predicted body weight (PBW) below 200 mL (i.e. height inferior to 134cm for a man and 139cm for a woman)
• •Moribund patient, i.e. not expected to survive 24 hours despite intensive care
• •Previous hypersensitivity or anaphylactic reaction to sevoflurane or to the intravenous sedation agent routinely used in the participating ICU (such as midazolam, propofol, or dexmedetomidine)
• •Absolute contra-indications to the intravenous sedation agent routinely used in the participating ICU (such as midazolam, propofol, or dexmedetomidine)
• •Medical history of malignant hyperthermia
• •Long QT syndrome at risk of arrhythmic events
• •Medical history of liver disease attributed to previous exposure to a halogenated agent (including sevoflurane)
• •Suspected or proven intracranial hypertension
• •Enrollment in another interventional trial with direct impact on oxygenation